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Growth and development affect drug-metabolizing enzyme activity thus could alter the metabolic profile of a drug. 
Traditional studies to create metabolite profiles and study the routes of excretion are unethical in children due 
to the high radioactive burden. To overcome this challenge, we aimed to show the feasibility of an absorption, 
distribution, metabolism, and excretion (ADME) study using a [14C]midazolam microtracer as proof of concept in 
children. Twelve stable, critically ill children received an oral [14C]midazolam microtracer (20 ng/kg; 60 Bq/kg) while 
receiving intravenous therapeutic midazolam. Blood was sampled up to 24 hours after dosing. A time-averaged 
plasma pool per patient was prepared reflecting the mean area under the curve plasma level, and subsequently 
one pool for each age group (0–1 month, 1–6 months, 0.5–2 years, and 2–6 years). For each pool [14C]levels were 
quantified by accelerator mass spectrometry, and metabolites identified by high resolution mass spectrometry. 
Urine and feces (n = 4) were collected up to 72 hours. The approach resulted in sufficient sensitivity to quantify 
individual metabolites in chromatograms. [14C]1-OH-midazolam-glucuronide was most abundant in all but one 
age group, followed by unchanged [14C]midazolam and [14C]1-OH-midazolam. The small proportion of unspecified 
metabolites most probably includes [14C]midazolam-glucuronide and [14C]4-OH-midazolam. Excretion was mainly 
in urine; the total recovery in urine and feces was 77–94%. This first pediatric pilot study makes clear that using a 
[14C]midazolam microtracer is feasible and safe to generate metabolite profiles and study recovery in children. This 
approach is promising for first-in-child studies to delineate age-related variation in drug metabolite profiles.
Drug development consists of several stages, including establishing 
the absorption, distribution, metabolism, and excretion (ADME), 
as well as the efficacy and safety of the drug. Importantly, 
metabolites of the parent drug may also contribute to efficacy and 
safety.1 A general approach to study overall drug disposition is by 
performing a mass balance and metabolite profiling study using 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Growth and development affect drug-metabolizing enzyme 
activity thus could alter the metabolic profile of a drug. Traditional 
studies to create metabolite profiles and study the routes of excre-
tion are unethical in children due to the high radioactive burden.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Is it feasible to create metabolic profiles of midazolam using 
a [14C]midazolam microtracer in children?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This first pediatric pilot study makes clear that using a [14C]
midazolam microtracer is feasible and safe to generate metabo-
lite profiles and study recovery in children.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Using a pediatric [14C]microtracer study approach is prom-
ising for first-in-child studies to delineate age-related variation 
in drug metabolite profiles. Also, such an approach may reduce 
the need for animal studies. Subsequently, metabolic profiles in 
other vulnerable populations whose drug metabolism and dis-
position differ from those in healthy adults can be studied using 
this study design, such as elderly and pregnant women.
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radiolabeled drug. Using this approach, metabolic pathways can 
be determined and quantitatively evaluated (i.e., clearance path-
ways delineated), and the quantitative and comprehensive pro-
file of metabolites in plasma can be described. The latter data set 
serves as a starting point for addressing whether the metabolites 
to which humans are exposed had also been present in labora-
tory animal species utilized in toxicological evaluations; i.e., the 
"MIST (Metabolites in Safety Testing) issue." The radioprofile of 
metabolites in plasma is used to determine which, if any, circu-
lating metabolites can be considered quantitatively important and 
thus require further evaluation, usually beginning with a compar-
ison of exposures between humans and animals at steady state. If 
human exposure exceeds animal exposures, then further safety 
evaluation of the metabolite may be warranted.
In 2008, the US Food and Drug Administration (FDA) recom-
mended that regarding the nonclinical safety of drug metabolites 
the exposure threshold for further metabolite characterization 
for an individual metabolite must be >  10% of the estimated 
parent-drug exposure. In 2009, the International Conference on 
Harmonisation (ICH) M3 guideline (R2) altered this threshold 
significantly to > 10% of the estimated total-drug exposure, which 
was included in the FDA guideline in 2016.2,3
The disposition of a drug is driven by processes such as drug me-
tabolism, drug transport, glomerular filtration, and body composi-
tion. These processes are subject to age-related changes reflecting 
growth and maturation along the pediatric continuum.4,5 Most 
drug-metabolizing enzymes and drug transporters act differently 
in neonates than in older children or adults, and the maturational 
patterns are isoform-dependent.4,6–10 Children’s metabolism may 
not only be slower or faster than that of adults but may also use 
different compensatory pathways. The resulting metabolite pro-
files could contain metabolites that have not yet been identified 
or are ≤ 10% of the total drug exposure in adults, yet are present, 
disproportionately present or even represent >  10% of the total 
drug exposure in children. This mechanism is most obvious for 
paracetamol, whose metabolism switches from mainly sulfation to 
glucuronidation from birth to 12 years of age.11 Glucuronidation is 
underdeveloped in newborns; hence, sulfation is used as a compen-
satory pathway. In newborns, the exposure to paracetamol-sulfate 
is higher than that to paracetamol-glucuronide, whereas in adults 
this is the other way around. Similarly, the metabolite pattern of 
sirolimus differs between children and adults. Studies have found 
that di-demethylated and hydroxy-desmethyl metabolites were not 
present in children but were present in adults, most likely due to 
maturation of cytochrome P450 (CYP) 3A.12,13 Lastly, the de-
methylation of caffeine by CYP1A2 increases with age, as in new-
borns caffeine is almost completely excreted by renal clearance of 
the parent drug, while in adults caffeine is many metabolically 
cleared.14,15 As in general the metabolites differ in terms of efficacy 
and toxicity,16 knowledge on metabolite profiles in children is cru-
cial for applying effective and safe pediatric drug therapy.
Metabolite profiles are typically generated by human radiola-
beled ADME studies, by analyzing plasma, urine, or feces samples 
with liquid chromatography with fraction collectors, followed by 
offline radioactivity detection using liquid scintillation counting.16 
For this latter technique, a high radioactive dose of 100 microcurie 
(µCi) in humans is needed. Just recently, advances mainly in ana-
lytical technology have enabled new approaches to ADME studies 
with less radioactivity exposure.16,17 By using [14C]microtracers 
concurrently administered with a therapeutic dose, metabolites 
can be identified and quantified by accelerator mass spectrometry 
(AMS) with a radioactivity exposure of even less than 0.1 µCi.18,19
The amount of radiolabeled dose that is ethically justified to 
be administered to human volunteers participating in clinical tri-
als has been risk classified by the International Commission on 
Radiological Protection (ICRP) (Table 1).20 The use of [14C]la-
beled microtracers with AMS quantification not only justifies ear-
lier radioactive exposure during drug development, but may also 
serve to derive metabolite profiles for vulnerable populations like 
newborns, for which 100 µCi levels would not be ethically accept-
able, even in a late stage of drug development. Various pediatric 
microtracer studies to study the pharmacokinetics of [14C]labeled 
compounds have already been successfully conducted.11,21–24 Yet, 
to the best of our knowledge, pediatric ADME microtracer studies 
with [14C]labeled compounds to create complete metabolite pro-
files have not yet been performed.
Midazolam is a drug with well-known metabolism in adults and 
is widely used as a marker for CYP3A4/5 activity, a developmen-
tally regulated phase 1 metabolizing enzyme, with lower activity 
in neonates than in adults.25 We hypothesized that using an oral 
[14C]midazolam microtracer as an example-compound in children 
receiving therapeutic intravenous midazolam for clinical needs 
would permit to generate metabolite profiles of midazolam in chil-
dren and study routes of excretion. Therefore, we aimed to explore, 
as a proof of concept, the feasibility of an ADME microtracer 




This study (EudraCT 2014-003269-46) was part of the ZonMw Priority 
Medicines for Children project "Pediatric microdosing: elucidating 
age-related changes in oral absorption to guide dosing of new formu-
lations," described in previous publications.11,21,26 The study was ap-
proved by the Dutch Central Committee on Research Involving Human 
Subjects (The Hague, The Netherlands). All parents or legal guardians 
provided prior to any study-specific procedures written informed con-
sent for their child to be included. The Dutch Nuclear Research and 
Service Group estimated the radiation exposure for a single microtracer 
of 60 Bq/kg (equivalent to an adult study of 0.1 µCi) and < 1 µSv and are 
allowed in this population according to the ICRP (Table 1).20,27 We ex-
plained to the parents and legal guardians that the radiation exposure of 
a single microtracer is almost negligible compared with the yearly mean 
background exposure 2,600 µSv in the Netherlands in 2013.28
Subjects
Patients admitted to the pediatric intensive care unit of the Erasmus 
MC – Sophia Children’s Hospital were considered for inclusion. The 
following inclusion criteria applied: age from birth (postmenstrual 
age  >  36  weeks) up to 6  years of age, bodyweight  >  2.5  kg, clinical 
need for intravenous midazolam, and an indwelling arterial line in 
place enabling blood sampling. Exclusion criteria were the following: 
anticipated death in 48 hours, extra corporeal membrane oxygenation 
treatment, circulatory failure (defined by the administration of ≥ 1 va-
sopressor drug, or increase of a vasopressor drug in the last 6  hours), 
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kidney failure (according to the Pediatric Risk, Injury, Failure, Loss, 
End stage renal disease (pRIFLE) criteria, i.e., estimated creatinine 
clearance decreased by 75% or a urine output of <  0.3  mL/kg/hour 
for 24 hours or anuria for 12 hours), liver failure (defined by aspartate 
aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2 
times the upper limit for age), gastrointestinal disorders, or comedi-
cation known to interact with midazolam (according to the Flockhart 
Table29).
Study procedures
A single [14C]midazolam dose was administered as an oral microtracer 
via the enteral feeding tube. Intravenous (IV) exposure was at therapeu-
tic levels in the context of clinical care, which allowed identification 
of metabolites by high resolution mass spectrometry (hrMS). The IV 
therapeutic midazolam dose was prescribed by the treating physician 
for clinical purposes and was adjusted on the guidance of validated se-
dation scores and according to a standardized sedation titration proto-
col. According to this protocol, midazolam bolus doses varied between 
0.05 and 0.2 mg/kg and the continuous infusion rate between 0.05 and 
0.3 mg/kg/hour. Blood samples were taken pre-dose and up to 24 hours 
after administration of the [14C]midazolam microtracer. The maximum 
number of study-specific blood samples was limited to eight per subject, 
and the maximum amount of blood could not exceed the European 
Medicines Agency (EMA) guidelines (maximum of 1% of the total 
blood volume at any time and a maximum 3% during a period of 4 weeks 
where the total volume of blood is estimated at 80–90 mL/kg).30 The 
blood samples were centrifuged and plasma was stored at −80°C until 
analysis. Urine was collected from patients with a urinary catheter in 
place for clinical reasons. It was collected with a maximum of 72 hours 
after [14C]midazolam administration or until the urinary catheter was 
removed. The nurses noted the urine volumes in the clinical electronic 
patient record. One sample (2 mL) was stored at −80°C until analysis. 
As long as urine was collected, also diapers were collected for the pur-
pose of studying the recovery in feces. The diapers were stored at −80°C 
until analysis.
Radiopharmaceutical preparation
Non–good manufacturing practice [14C]midazolam was synthesized and 
the quality characterized by Selcia Ltd, Shelley, United Kingdom, at a spe-
cific activity of 1,033 MBq/mmol (equal to 2.85 MBq/mg). The chemical 
name is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1-14C]imidazo[l,5-a]
[l,4]benzodiazepine-hydrochloride, and it was brought in ethanol solu-
tion (96%). In the department of Radiology and Nuclear Medicine at 
the VU University Medical Center (Amsterdam, The Netherlands) the 
solution was further diluted to the required concentration with sodium 
chloride 0.9% solution (Fresenius Kabi, Zeist, The Netherlands) to pro-
vide a good manufacturing practice drug product. The final [14C]midaz-
olam concentration was 210–270 Bq/mL, with 1 Bq being equivalent to 
0.31 ng [14C]midazolam.
Metabolite profiles
Subjects and plasma samples. We created four age groups: 0–28 days; 
1–6 months; 6 months–2 years; 2–6 years. First a time-averaged plasma 
pool per patient (area under the curve (AUC)0-t where t is the last sam-
pling time point) was prepared according to the Hamilton method,31,32 
after which age group pools were generated by equi-volumetric pooling. 
A time-averaged pool consists of aliquots from individual samples that 
form one composite sample. The volume of the aliquot taken from each 
individual plasma sample was determined by the time interval between 
drawing of the samples. The final time-averaged pool reflects the mean 
plasma level of the testing period (0–≈24 hours).
Identification of metabolites and quantification [14C]levels. In 
total, 150  µL of the plasma pool was added to 600 µL methanol and 
centrifuged. The supernatant was evaporated to dryness and redis-
solved in 80 µL 95/5 1 mM ammonium formate in MilliQ + 5% ace-
tonitrile (ACN) / ACN. The plasma extracts were injected on an ultra 
performance liquid chromatography (20 µL/injection) with a gradient 
runtime of 30  minutes, allowing absolute metabolite separation. The 
flow was split directly after ultra performance liquid chromatography 
separation diverting one line coupled to a Q-Exactive hrMS (Thermo 
Fisher, Waltham, MA; in-line) for metabolite identification and one 
line to a fraction collector (90 fractions in 30 minutes) for subsequent 
AMS (off-line) (1MV Tandetron) [14C] level quantification. For each 
time-averaged pool, 90 fractions were collected (0–20 minutes 4 frac-
tions/min; 20–30 minutes 1 fraction/min) and transferred to a tin foil 
cup and evaporated to dryness prior to [14C]level quantification.
Quantification [14C]levels with AMS. [14C]levels were quantified as 
described previously.32 In brief, the tin foil cups were combusted on an 
elemental analyzer (Vario Micro; Elementar, Langenselbold, Germany). 
Generated carbon dioxide (CO2) was transferred to a home-built gas in-
terface, composed of a zeolite trap and syringe.32 CO2 was adsorbed to 
the trap on the interface; and after heating of the trap, the CO2 was trans-
ferred to a vacuum syringe using helium. A final CO2/helium mixture of 
6% was directed to the AMS ion source, at a pressure of 1 bar and a flow 
of 60 µL/minute. A 1-MV Tandetron AMS (High Voltage Engineering 
Europe B.V., Amersfoort, The Netherlands)33 was used. To determine 
the true amount of radioactivity in each fraction, the measured [14C]/
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[12C] ratios were multiplied by the corresponding total carbon measure-
ment of the elemental analyzer.
hrMS metabolite identification. A Q-exactive hrMS (Thermo Fisher) 
was used for metabolite identification. The Q-exactive hrMS was op-
erated in positive ion mode at a resolution of 35,000 in mass spectrom-
etry (MS) and 17,500 in MS2. The used mass range was from 100 to 
850  m/z. For data dependent MS2, an isolation window of 2.0  m/z 
was used. The collision voltage was set at 35 eV. For mass measurement 
of metabolites, the mass range was from 200 to 2,000 m/z. The min-
imum automatic gain control was set at 5E3 and the intensity thresh-
old at 1E5. Compound Discoverer (Thermo Fisher) was used for data 
processing.
Mass balance
With regard to the mass balance part, routes of excretion were studied by 
determining the recovery of the administered [14C]midazolam dose in 
urine and feces. Total [14C]levels in urine were measured by AMS as de-
scribed in the section “Quantification [14C]levels with AMS.” Recovery 
in urine was calculated by multiplying the [14C]levels by the total urine 
volume. Diapers were extracted using ethanol:water (25:75). To optimize 
extraction, the diapers were first inverted with the inside facing out. The 
diapers were individually transferred to a bucket and one liter of the ex-
traction solvent was added. With lid closed, the bucket was placed on a 
horizontal shaker for 7 days during which the analytes were extracted. 
After completion, the samples were homogenized with an Ultra-Turrax 
and a small part of the sample was transferred to a tin foiled cup for di-




For the original study (see the section Study design) 96 patients 
were eligible based on the inclusion and exclusion criteria, of 
which parents of 46 patients consented to let their child par-
ticipate in the study. For this substudy, the samples of the first 
12 included patients were selected, which had a median (range) 
age of 13.1 (1.3–218.6) weeks and bodyweight of 5.6 (3.1–17.0) 
kg. In Table  2 the patient characteristics can be found, and 
the detailed characteristics per individual patient in Table S1. 
The age groups/time-averaged pools 0–28  days, 1–6  months, 
6  months–2  years and 2–6  years consisted of 4, 5, 1, and 2 
patients, respectively. Each received an oral [14C]midazolam 
dose of 59.6 (55.7–66.3) Bq/kg, equal to 18.7 (17.5–20.8) ng/
kg, in addition to therapeutic continuous IV midazolam, for 
which the doses were determined by the treating physician, ac-
cording to the pediatric intensive care unit sedation protocol 
(0.05–0.2 mg/kg bolus and 0.05–0.3 mg/kg/hour continuous 
infusion).
Metabolite profiles
We were able to identify metabolite profiles for each age group 
(Figure 1 and Table 3). Two prominent peaks and some smaller 
peaks were present in the AMS radio chromatogram for each 
group (Figure 1), showing the amount of radioactivity for [14C]
labeled compounds/metabolites. All MS/MS spectra were consis-
tent with those of the available reference standards. In the three 
youngest age groups, [14C]1-OHMG was the most abundant, 
followed by the unchanged [14C]midazolam. In the age group 
2–6  years, the unchanged [14C]midazolam was most abundant, 
followed by [14C]1-OHMG. For all age groups, the quantities of 
[14C]1-OHM were much lower than [14C]midazolam and [14C]1-
OHMG. For all age groups, there was a small proportion of un-
specified metabolites of which individual peaks were < 10% of the 
total drug-related material.
Mass balance
Table  4 presents the mass balance results of urine samples and 
diapers of four patients. The main route of excretion was renal, 
resulting in a recovery of 49–72%. The total recovery of the [14C]
midazolam dose in urine and feces was 77–94%.
DISCUSSION
With this proof-of-concept study, we have shown that it is feasi-
ble to perform an ADME study using a [14C]microtracer study 
design in pediatric patients. We used an oral [14C]midazolam 
microtracer concurrently administered with therapeutic IV 
midazolam as an example-compound, and successfully created 
metabolite profiles and studied routes of excretion by the use 
of AMS and hrMS. The metabolite profiles differed per age 
group and consisted of the parent drug, two major metabolites 
1-OHM and 1-OHMG, and small proportions of unspecified 
fraction of metabolites that were < 10% of the total drug-related 
Table 2 Characteristics of patients included in the analysis 
Patient characteristics
Number of patients (n) 12
Postnatal age (weeks) 13.1 (1.3–218.6)
Weight (kg) 5.6 (3.1–17.0)
Gender (M/F) 8/4















PIM −3.1 (−4.7 to −0.6)
Laboratory values at day of administration [14C]midazolam
Plasma creatinine (µmol/L) 38 (25–63)
AST (U/L) 53 (16–309)
ALT (U/L) 17 (7–114)
CRP (mg/L) 21 (3–123)
Data are presented as median (range) or number.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, 
C-reactive protein; PELOD, Pediatric Logistic Organ Dysfunction; PIM, Pediatric 
Index of Mortality; PRISM, Pediatric Risk of Mortality.
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exposure. The recovery of the administered dose in urine and 
feces was 77–94%.
Our finding that in the three youngest age groups the systemic 
exposure to 1-OHMG was most abundant, followed by midaz-
olam and 1-OHM, is in line with literature and supports the feasi-
bility of our microtracer approach. De Wildt et al. have shown that 
up to 6 hours after oral administration of midazolam in preterm 
neonates the fraction of urinary excreted midazolam, 1-OHM 
and 1-OHMG was median (range) 0.11% (0.02–0.59%), 0.02% 
(0.00–0.10%), and 1.69% (0.58–7.31%), respectively.34 Those 
data indirectly reflect that, similarly to our results, the systemic 
exposure to 1-OHMG was the highest, followed by midazolam 
and 1-OHM. Also in adults, the major metabolite found in urine 
was 1-OHMG—accounting for 60–80% of the administered 
dose.35 Based on literature, we expect that the small portion of un-
specified fraction included known midazolam metabolites, such 
as midazolam-glucuronide and 4-OH-midazolam.36,37 For adults, 
nearly 90% urinary recovery after oral dosing of midazolam has 
Figure 1 Metabolite profiles as presented by the radio chromatogram of [14C] levels after administration of an oral [14C]midazolam microtracer 
to children. The population was divided in four age groups/Hamilton pools: 0–1 month, 1–6 months, 6 months–2 years, and 2–6 years. 
[14C]levels were quantified with accelerator mass spectrometry. 1-OHM, 1-OH-midazolam; 1-OHMG, 1-OH-midazolam-glucuronide. The 
corresponding high resolution mass spectrometry retention times can be found in Table 4.
Table 3 The parent and metabolite exposures in percentage of the total drug-related exposure of an oral [14C]midazolam 
microtracer in four age groups
Midazolam (%) 1-OHM (%) 1-OHMG (%) Unspecified (%)
0–1 month 40.7 5.0 42.7 11.5
1–6 months 26.2 2.5 63.0 8.3
6 months–2 years 27.0 2.5 59.2 11.3
2–6 years 56.1 5.6 32.0 6.3






Total fraction of the administered 
dose recovered in urine and feces
Total  
recovery (Bq)




Fraction of  
administered dose
1 20 155 0.74 6.21 0.03 0.77
2 48 124 0.74 31.5 0.19 0.93
3 48 81 0.49 64.1 0.39 0.88
4 71 330 0.92 7.12 0.02 0.94
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been found,38 which is in concordance with our findings that re-
covery was highest in urine, and the total recovery in urine and 
feces was 77–94%. More specifically for our results, the lowest 
recovery of 77% was found for a patient whose urinary catheter 
had been removed after 20 hours. A longer sampling time could 
have resulted in a higher recovery as the excretion may not yet 
have been complete. While the relative distribution of systemic 
exposure to metabolite and parent drug was similar in the three 
youngest age groups, the absolute distribution was not simi-
lar. The sample size of this pilot / proof-of-concept study is too 
small, however, to draw conclusions about age-related changes 
in the absolute metabolite profiles, as for example the age group 
6 months–2 years is underrepresented with only one patient.
The introduction of ADME studies that utilize [14C]microtrac-
ers in drug development has resulted in an improvement in drug 
development for adults, with earlier human metabolism studies in-
creasing the safety as well as efficacy of drugs.16 Finding a unique 
human metabolite at a late stage in drug development, that had not 
at all or at a disproportional level been detected in animals during 
nonclinical drug evaluation introduces safety and toxicity concerns, 
as human volunteers may be exposed to this metabolite whose char-
acteristics are not known.17 In addition, this may cause considerable 
delay in drug registration because addition of toxicological assess-
ments might be required. Current regulatory guidelines for drug 
development also mandate scientists to submit a pediatric drug 
development program to the regulators.39 Although for midazolam 
no unique metabolite was found in children, we can speculate that 
this may not be true for other drugs. Thus, conducting an ADME 
study with a [14C]microtracer is a potentially valuable addition to 
pediatric drug development that may secure drug safety and effi-
cacy, and avoiding delay in drug registration. Also, ADME studies 
using the microtracer approach may lead to a reduction in animal 
radiolabel studies.16 Currently, juvenile animals are often used to 
predict drug disposition and metabolism in children. Besides the 
fact that findings in juvenile animals cannot be directly translated to 
human children as they differ widely in terms of drug disposition,40 
pediatric microtracer ADME studies may also reduce the need for 
animal studies. Subsequently, metabolic profiles in other vulnerable 
populations, such as elderly and pregnant women whose drug me-
tabolism and disposition differ from those in healthy adults can be 
studied using the study design described in this report.41,42
To conclude, with this study we have shown that it is feasible to 
use a [14C]microtracer ADME approach in pediatrics. By simul-
taneous identification of metabolites and quantification of [14C]
levels, we were able to safely generate metabolite profiles of midaz-
olam and study the routes of excretion in children. This approach 
is promising to improve safety and efficacy of drug therapy for chil-
dren and other vulnerable populations.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
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